Plant-derived extracellular vesicles as bioactive nanoplatforms: Biogenesis, therapeutic evidence, and translational challenges Authors: Jingcheng Yu, Yuren Shen, Hao Jia Published: 2026 ABSTRACT BackgroundPlant-derived extracellular vesicles (PDEVs) are nanoscale membrane vesicles isolated from edible or medicinal plants. They have attracted interest because they combine endogenous biological activity with the practical advantages of scalable natural nanocarriers.ObjectiveThis mini-review examines PDEVs from a pharmaceutical development perspective rather than as a broad catalogue of biological observations. We focus on how vesicle source, isolation workflow, cargo composition, and route of administration affect therapeutic interpretation and translational feasibility.ContentWe summarize PDEV biogenesis, isolation, characterization, and interaction with mammalian cells, and compare PDEVs with mammalian exosomes and synthetic liposomes. Representative preclinical studies in bone repair, neurological injury, inflammatory and gastrointestinal disease, cancer, and renal stone disease are critically evaluated, with attention to dose heterogeneity, model limitations, and mechanistic strength. We also discuss PDEVs as engineered carriers for exogenous therapeutics and revisit the debate around dietary plant miRNA uptake and cross-kingdom regulation.ConclusionPDEVs offer several practical advantages, including oral compatibility, scalable sourcing, and potential dual use as intrinsic therapeutics and delivery systems. The field remains limited by inconsistent terminology, non-standardized purification, incomplete pharmacokinetic profiling, and scarce clinical data. Future translation will require rigorous quality control, reproducible potency assays, comprehensive biodistribution studies, and clear regulatory positioning. Introduction Plant-derived extracellular vesicles (PDEVs) comprise a structurally diverse population of lipid-bilayer vesicles released from plant tissues and apoplastic compartments. The field still uses several overlapping terms; the same type of preparation may be described as plant extracellular vesicles, exosome-like nanoparticles, nanovesicles, or plant-derived vesicle-like nanoparticles [[1], [2], [3], [4]]. Despite this terminology problem, PDEVs have become attractive candidates for pharmaceutical research. Plant biomass is accessible and scalable, many preparations are compatible with oral delivery, and isolated vesicles can retain endogenous lipids, proteins, metabolites, and small RNAs with biological activity [[5], [6], [7], [8]]. Recent reviews have summarized the general biology of PDEVs, oral delivery, regenerative medicine, tissue engineering, and nanomedicine [[9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20]]. Many of these articles mainly catalogue disease models or emphasize one cargo class, especially miRNAs. Here, we take a different approach. This review examines PDEVs from the perspective of pharmaceutical development, with emphasis on preparation quality, carrier function, therapeutic evidence, and translational feasibility [[20], [21], [22], [23]]. The conceptual scope of this review is summarized in Fig. 1.Fig. 1Conceptual overview of plant-derived extracellular vesicles (PDEVs) as bioactive nanoplatforms. The schematic summarizes major plant sources, isolation and characterization workflows, representative cargo classes, mammalian-cell interaction, therapeutic applications, engineered drug delivery, and key translational considerations. The figure is original and was created by the authors. Conceptual overview of plant-derived extracellular vesicles (PDEVs) as bioactive nanoplatforms. The schematic summarizes major plant sources, isolation and characterization workflows, representative cargo classes, mammalian-cell interaction, therapeutic applications, engineered drug delivery, and key translational considerations. The figure is original and was created by the authors. Biogenesis, isolation, and characterization of PDEVs Biogenesis and nomenclature Plant EV biogenesis appears to share some features with mammalian exosome formation, especially multivesicular-body-related pathways, but a direct analogy should be made with caution. In plants, vesicle release has been linked to endosomal trafficking, fusion of multivesicular bodies with the plasma membrane, and possibly direct budding under stress or defense conditions [3,24]. This biology matters because biogenesis shapes cargo composition and functional heterogeneity. It also explains why terminology alone is insufficient. Preparations isolated from plant juices or homogenates may contain bona fide extracellular vesicles together with membrane fragments and other colloidal nanoparticles. For this reason, source tissue and isolation method often provide more useful information than the label applied to the vesicle preparation [2,11,12]. Isolation strategies Most PDEV studies rely on differential centrifugation or ultracentrifugation, usually combined with filtration and, less often, density gradients or size-exclusion chromatography [1,2,12]. Differential ultracentrifugation is practical and widely used, but it can enrich non-vesicular contaminants and promote aggregation. Density gradients improve purity but reduce throughput. Size-exclusion chromatography better preserves colloidal integrity, although scale-up remains challenging. Precipitation-based methods are convenient but usually sacrifice compositional specificity. These trade-offs are not technical details alone; in many studies, reported therapeutic differences may reflect isolation workflows as much as plant source biology. The absence of a plant-specific consensus framework, comparable to MISEV guidance for mammalian EVs, remains a major limitation [25,26]. Characterization and quality control Characterization typically includes transmission electron microscopy, nanoparticle tracking analysis, dynamic light scattering, and zeta-potential measurement, followed by profiling of proteins, lipids, metabolites, or small RNAs [1,[11], [12], [13], [14]]. Unlike mammalian EVs, PDEVs do not yet have universally accepted marker panels. Proteins such as PEN1 or TET8 are informative in plant model systems, but their utility across edible plant species remains uncertain [3,4,24]. This gap complicates batch qualification and makes it difficult to compare studies that claim to analyze similar vesicle populations. Storage adds another source of variation, as preservative choice and temperature can affect vesicle stability [27]. For pharmaceutical development, yield alone is not an adequate release criterion; purity, structural integrity, and retained bioactivity need to be evaluated together. Cargo composition and interaction with mammalian cells PDEVs should not be treated simply as empty carriers. Their membranes are enriched in phospholipids, galactolipids, and other plant lipids, and their luminal contents may include proteins, enzymes, phytochemicals, and multiple RNA classes [8,11,19,24]. This compositional complexity is both a strength and a translational problem. A preparation may act through vesicle architecture, one dominant cargo class, or a combined effect that is difficult to separate experimentally. In many reports, causality is inferred from cargo association rather than tested through formal cargo-depletion or rescue experiments. Cellular uptake has been attributed to endocytosis, phagocytosis, macropinocytosis, and membrane fusion, depending on the plant preparation and recipient cell type [7,28]. Grapefruit- and ginger-derived vesicles have been useful for demonstrating intestinal and hepatic delivery after oral administration [28]. These findings argue against viewing PDEVs as inert materials that only transit through the gut lumen. Still, tissue tropism remains incompletely defined, and many biodistribution studies use lipophilic dyes that can overestimate vesicle-specific uptake if free dye is not rigorously excluded. The most debated issue in PDEV biology is the cross-kingdom transfer of plant miRNAs. Early studies suggested that dietary plant miRNAs could enter mammalian circulation and regulate host transcripts [29,30]. Other studies challenged this conclusion and reported low or undetectable oral bioavailability under several conditions [31,32]. More recent work, including SIDT1-dependent gastric uptake, suggests that uptake may be context-dependent rather than universally absent [28]. From a pharmaceutical standpoint, the key question is not whether every dietary plant miRNA is functional in mammals, but whether vesicle-encapsulated RNAs behave differently from free dietary RNA. That question still requires reproducible pharmacokinetic testing. Therapeutic evidence across disease systems The therapeutic literature is still largely preclinical. Even so, several patterns are visible: PDEVs appear most convincing in settings that benefit from oral or local delivery, and reported efficacy is usually linked to anti-inflammatory, redox-modulating, regenerative, or barrier-stabilizing effects rather than to one universal pathway. Bone metabolic disorders Bone repair is one of the better developed application areas. Yam-derived vesicles stimulated osteoblast differentiation and attenuated bone loss in mice through BMP-2/MAPK/Runx2 signaling [33]. Sea buckthorn-derived extracellular vesicles promoted osteogenic differentiation and bone regeneration, with aau-miR168 proposed as an upstream effector acting through LBH/RUNX2 [34]. Ginseng-derived exosome-like nanovesicles suppressed osteoclast differentiation in an LPS-driven osteoporosis model and were linked to NF-kappaB/MAPK inhibition [35]. These studies suggest that PDEV activity in bone is not restricted to one plant source or one cell lineage. Direct comparison remains difficult, however, because source material, purification workflow, dose units, and formulation format differ across studies. Neurological injury and neurodegeneration In neurological models, the evidence is mechanistically plausible but fragmented. Sophora-derived exosomes incorporated into a hydrogel improved spinal cord repair in vivo, with benefits attributed to reduced oxidative stress and a more permissive regenerative microenvironment [36]. Carrot-derived nanovesicles reduced oxidative injury and mitochondrial apoptosis in neuroblastoma-based Parkinsonian models [37], whereas Salvia hairy root-derived vesicles showed neuroprotective activity in a cellular model of Parkinson's disease and were linked to a complex triterpenoid-rich cargo profile [38]. The common feature is not a shared source or a single decisive pathway, but repeated convergence on redox control and cell-survival signaling. It remains unclear whether the active determinant is a phytochemical, an RNA species, a protein cargo, or the vesicle membrane itself. Inflammatory, gastrointestinal, and hepatobiliary disease The gastrointestinal tract is a natural target for PDEVs because it reduces the delivery problem. Turmeric-derived nanovesicles alleviated ulcerative colitis, in part by shifting macrophage polarization, suppressing NF-kappaB activity, and improving epithelial barrier function [39]. Ginger-, grape-, and broccoli-derived particles have shown anti-colitic activity through related but distinct mechanisms, including Nrf2/HO-1 signaling, intestinal stem-cell support, and dendritic-cell AMPK activation [[40], [41], [42], [43]]. Garlic-chive vesicle-like nanoparticles further broadened the inflammatory spectrum by suppressing NLRP3-driven pathology [44]. Beyond colitis, recent analyses indicate that PDEVs can reshape inflammatory microenvironments by regulating macrophage polarization, cytokine secretion, oxidative stress, epithelial barrier repair, and gut microbiota composition [22,23]. This immunomodulatory dimension is not restricted to the gut. Ginger-derived particles reduced hepatic injury markers in alcohol-injury models [40], and grapefruit-derived nanoparticles have been used for immune-cell-directed delivery in vivo [8]. These findings support broader immune reprogramming as a plausible PDEV activity, but the mechanistic depth remains uneven. Most studies report pathway-associated readouts, whereas fewer define a dominant cargo determinant or a pharmacological dose-response relationship. Evidence for PDEVs in human infectious diseases is less mature. Plant EVs clearly participate in plant-pathogen communication [5,24], but direct therapeutic evidence in mammalian infectious-disease models remains limited. We therefore regard infectious disease as an important future direction rather than an established therapeutic category. Cancer The use of PDEVs in oncology is still early but expanding. Lemon-derived vesicles inhibited cancer-cell proliferation and suppressed tumor growth in gastric cancer models [45], while grapefruit-derived lipid nanoparticles have been loaded with therapeutic agents and delivered in vivo with improved efficacy relative to free drug in selected models [8]. Recent work has also framed PDEVs as direct anti-proliferative agents through endogenous cargo and as engineered carriers for chemotherapeutics, siRNAs, and immunomodulatory agents [21,46]. The current oncology evidence should be interpreted with caution. Available studies suggest that PDEVs may influence tumor growth through apoptosis induction, inflammatory signaling, immune regulation, drug delivery, and remodeling of the tumor microenvironment. However, these findings remain scattered across different tumor models and plant sources, and a coherent mechanistic framework has not yet been established [46]. PDEVs are therefore better regarded at present as biologically active nanoplatforms with potential to support existing cancer therapies, rather than as independent anticancer agents. Urinary disease Compared with the intestinal literature, urinary applications are less mature. Lemon-derived extracellular vesicle-like nanoparticles reduced crystal-associated injury and slowed the progression of nephrolithiasis in renal tubular models, with antagonism of endoplasmic-reticulum stress proposed as a central mechanism [47]. Earlier work on lemon-derived vesicles also documented antioxidant activity in mammalian cells [48]. These findings are intriguing because PDEVs may act through both physicochemical and biological routes: direct effects on crystal behavior and indirect protection of injured tubular epithelium. The evidence base, however, remains narrow and requires external replication. Representative preclinical studies are summarized in Table 1.Table 1Summary of representative preclinical studies on PDEVs across disease models.Table 1Plant sourceDisease modelKey cargo/componentProposed pathwayModel systemKey outcomeRefYamBone defect/osteoporosisIntrinsic vesicle componentsBMP-2/MAPK/Runx2In vitro + in vivoOsteoblast mineralization; bone loss attenuation33Sea buckthornBone regenerationaau-miR168LBH/RUNX2In vitro + in vivoBMSC osteogenic differentiation34GinsengOsteoporosisVesicle proteins/lipidsNF-kappaB/MAPKIn vivoOsteoclast differentiation inhibition35Sophora japonicaSpinal cord injuryFlavonoid-enriched componentsROS/NF-kappaBIn vivo hydrogelAxonal regrowth; microenvironment remodeling36CarrotParkinsonian cell injuryNot fully resolvedMitochondrial apoptosisIn vitroDose-dependent neuroprotection37Salvia miltiorrhizaParkinsonian modelTriterpenoid-rich cargo6-OHDA autoxidation/cell survivalIn vitro + in vivoNeuroprotection; anti-apoptosis38TurmericUlcerative colitismiRNA/lipidsNF-kappaB; M1-to-M2 shiftIn vitro + in vivoAnti-inflammation; barrier repair39GingerLiver injury/colitisLipids/shogaol-related cargoNrf2/HO-1In vitro + in vivoHepatoprotection; anti-colitis40, 41GrapeDSS-induced colitismiRNA/lipidsWnt/beta-cateninIn vivoIntestinal stem cell support42BroccoliDSS-induced colitisSulforaphane-related cargoAMPK/DC activationIn vivoDendritic-cell-mediated anti-colitis43Garlic chiveInflammatory diseaseLipid componentsNLRP3 inflammasomeIn vitro + in vivoInflammasome suppression44LemonGastric cancer modelLipids/proteinsApoptosis-related signalingIn vitro + in vivoTumor growth suppression45GrapefruitDrug delivery/inflammationLoaded methotrexateMacrophage-targeted deliveryIn vivoEnhanced efficacy; reduced toxicity8LemonNephrolithiasisLipids/proteinsER-stress antagonismIn vitroCrystal inhibition; tubular cytoprotection47 Table 1Summary of representative preclinical studies on PDEVs across disease models.Table 1Plant sourceDisease modelKey cargo/componentProposed pathwayModel systemKey outcomeRefYamBone defect/osteoporosisIntrinsic vesicle componentsBMP-2/MAPK/Runx2In vitro + in vivoOsteoblast mineralization; bone loss attenuation33Sea buckthornBone regenerationaau-miR168LBH/RUNX2In vitro + in vivoBMSC osteogenic differentiation34GinsengOsteoporosisVesicle proteins/lipidsNF-kappaB/MAPKIn vivoOsteoclast differentiation inhibition35Sophora japonicaSpinal cord injuryFlavonoid-enriched componentsROS/NF-kappaBIn vivo hydrogelAxonal regrowth; microenvironment remodeling36CarrotParkinsonian cell injuryNot fully resolvedMitochondrial apoptosisIn vitroDose-dependent neuroprotection37Salvia miltiorrhizaParkinsonian modelTriterpenoid-rich cargo6-OHDA autoxidation/cell survivalIn vitro + in vivoNeuroprotection; anti-apoptosis38TurmericUlcerative colitismiRNA/lipidsNF-kappaB; M1-to-M2 shiftIn vitro + in vivoAnti-inflammation; barrier repair39GingerLiver injury/colitisLipids/shogaol-related cargoNrf2/HO-1In vitro + in vivoHepatoprotection; anti-colitis40, 41GrapeDSS-induced colitismiRNA/lipidsWnt/beta-cateninIn vivoIntestinal stem cell support42BroccoliDSS-induced colitisSulforaphane-related cargoAMPK/DC activationIn vivoDendritic-cell-mediated anti-colitis43Garlic chiveInflammatory diseaseLipid componentsNLRP3 inflammasomeIn vitro + in vivoInflammasome suppression44LemonGastric cancer modelLipids/proteinsApoptosis-related signalingIn vitro + in vivoTumor growth suppression45GrapefruitDrug delivery/inflammationLoaded methotrexateMacrophage-targeted deliveryIn vivoEnhanced efficacy; reduced toxicity8LemonNephrolithiasisLipids/proteinsER-stress antagonismIn vitroCrystal inhibition; tubular cytoprotection47 Summary of representative preclinical studies on PDEVs across disease models. PDEVs as drug delivery carriers Carrier function beyond intrinsic bioactivity Much of the literature focuses on the endogenous therapeutic effects of PDEVs, but their use as engineered carriers for exogenous therapeutics is equally important. This dual function - intrinsic bioactivity combined with drug-loading capacity - distinguishes PDEVs from conventional synthetic nanocarriers. It also complicates regulatory positioning, because a single preparation may behave both as an active biological material and as a delivery vehicle. Delivery of small molecules Several studies have shown that plant-derived lipid or vesicle-like nanoparticles can encapsulate hydrophobic or amphipathic small molecules through co-incubation, sonication, or electroporation. Wang et al. showed that grapefruit-derived lipid nanoparticles loaded with methotrexate could be delivered to intestinal macrophages with improved anti-inflammatory efficacy and lower systemic toxicity compared with free drug [8]. Ginger-derived nanoparticles have also been explored for inflammatory bowel disease and colitis-associated cancer, including drug-loading strategies relevant to colon delivery [41]. The enrichment of phosphatidic acid and galactolipids in plant-derived membranes may facilitate incorporation of lipophilic drugs, although loading efficiency and release kinetics are not yet standardized across plant sources. Delivery of nucleic acids and proteins The potential of PDEVs as carriers for therapeutic RNA is particularly relevant as RNA-based medicine expands. Wang et al. demonstrated that ginger nanoparticle-derived lipid vectors carrying Dmt1-targeting siRNA reduced iron loading in a mouse model of hereditary hemochromatosis after oral administration [49]. This study provides proof-of-concept that plant-derived lipid carriers can protect nucleic acid cargo from gastrointestinal degradation and deliver functional RNA to target tissues. Protein delivery is less mature. Proteins are consistently detected in PDEV preparations, but engineered protein-loading studies remain limited and need stronger evidence for loading efficiency, retained bioactivity, and intracellular release. At present, small-molecule and RNA delivery are better supported than therapeutic protein delivery. Position relative to mammalian exosomes and synthetic liposomes The value of PDEVs as drug carriers should be assessed against established alternatives. Compared with mammalian exosomes, PDEVs avoid zoonotic risk, do not require expensive cell culture, and are often more compatible with oral administration [1,14,50]. Compared with synthetic liposomes - the most mature clinical nanomedicine platform - PDEVs carry intrinsic bioactive cargo that may provide synergistic effects alongside loaded drugs, but they also pose greater challenges in compositional control and batch-to-batch reproducibility [15,51,52]. A concise comparison is provided in Table 2.Table 2Comparison of PDEVs, mammalian exosomes, and synthetic liposomes from a pharmaceutical-development perspective.Table 2FeaturePDEVsMammalian exosomesSynthetic liposomesSource materialEdible or medicinal plantsMammalian cells or body fluidsSynthetic lipidsTypical size rangeOften 50-400 nmOften 30-150 nmFormulation-dependent, often 50-200 nmOral compatibilityRelatively favorableUsually limited without protectionVariable; formulation-dependentIntrinsic bioactivityYes; miRNAs, lipids, metabolites, proteinsYes; proteins, miRNAs, lipidsNo intrinsic biological cargoDrug-loading capabilityModerate; source- and method-dependentLow to moderateHigh and tunableScalabilityHigh agricultural scalabilityLimited by cell cultureHigh manufacturing scalabilityZoonotic riskLow/none from plant sourcePotentially source-dependentNoneBatch reproducibilityStill weak; source-dependentModerate; cell-source-dependentHigh under GMPRegulatory maturityPreclinical/unsettledDevelopingWell established for several productsMain bottleneckStandardization, potency assays, pharmacokineticsYield, purity, immunogenicity, scalabilityLack of intrinsic bioactivity; formulation optimization Table 2Comparison of PDEVs, mammalian exosomes, and synthetic liposomes from a pharmaceutical-development perspective.Table 2FeaturePDEVsMammalian exosomesSynthetic liposomesSource materialEdible or medicinal plantsMammalian cells or body fluidsSynthetic lipidsTypical size rangeOften 50-400 nmOften 30-150 nmFormulation-dependent, often 50-200 nmOral compatibilityRelatively favorableUsually limited without protectionVariable; formulation-dependentIntrinsic bioactivityYes; miRNAs, lipids, metabolites, proteinsYes; proteins, miRNAs, lipidsNo intrinsic biological cargoDrug-loading capabilityModerate; source- and method-dependentLow to moderateHigh and tunableScalabilityHigh agricultural scalabilityLimited by cell cultureHigh manufacturing scalabilityZoonotic riskLow/none from plant sourcePotentially source-dependentNoneBatch reproducibilityStill weak; source-dependentModerate; cell-source-dependentHigh under GMPRegulatory maturityPreclinical/unsettledDevelopingWell established for several productsMain bottleneckStandardization, potency assays, pharmacokineticsYield, purity, immunogenicity, scalabilityLack of intrinsic bioactivity; formulation optimization Comparison of PDEVs, mammalian exosomes, and synthetic liposomes from a pharmaceutical-development perspective. Relevance to pharmaceutical Design PDEVs are often compared with mammalian exosomes, but the comparison should be functional rather than rhetorical. Mammalian exosomes are biologically sophisticated and increasingly relevant to regenerative medicine and delivery science, yet they raise practical issues related to source control, cell-culture cost, batch variability, and potentially immunogenic surface components [50]. PDEVs do not solve all of these problems, but they shift the balance in three useful directions: lower source cost, easier access to orally compatible materials, and the possibility of combining carrier behavior with endogenous bioactivity [15,16]. The comparison with synthetic liposomes is equally important. Liposomes remain far ahead in manufacturing standardization, composition control, and regulatory familiarity [51]. PDEVs, by contrast, are compositionally rich but less defined. This is both an opportunity and a liability. A plant vesicle may deliver a therapeutic cargo without extensive reformulation, yet the same biological richness complicates quality control and mechanism assignment. Accordingly, PDEVs should be considered bioactive nanoplatforms with distinct pharmaceutical features, rather than simple natural equivalents of synthetic liposomes. Their value will depend on whether a therapeutic question benefits more from biological complexity or from precise compositional control [19]. From a formulation perspective, PDEVs appear most attractive for oral, mucosal, hydrogel-based, and local-regeneration applications [16,17]. This route-fit may prove more important than the broad claim that PDEVs are simply safer than mammalian vesicles. The most persuasive translational opportunities are likely to emerge where plant sourcing, delivery route, and disease biology align. Challenges and future horizons Standardization, dose, and pharmacokinetics The field still lacks harmonized standards for nomenclature, isolation, batch qualification, potency assays, and dose reporting. Doses are variously expressed as particle number, protein mass, starting plant mass, or formulation amount, which weakens cross-study comparison [[11], [12], [13], [14],25]. Pharmacokinetic data are also limited. Although oral uptake and intestinal or hepatic accumulation have been described in several models [14,28], systemic half-life, clearance pathways, and the fraction of intact vesicles reaching distal tissues remain poorly defined. These are not peripheral details; they determine whether PDEVs can be developed as reproducible medicines rather than as interesting biological extracts. Quality control, storage, and manufacturing For translation, three variables require tighter control than is common in current studies: source material, downstream processing, and storage. Plant species, cultivar, growth conditions, and tissue maturity can influence vesicle output and cargo composition [19,27]. Downstream processing then changes the recovered particle class, and storage conditions can alter stability and function [27]. Recent reviews increasingly frame PDEVs as a dual system - a source of natural bioactives and a delivery platform - but this also means that manufacturing changes may alter both the carrier and the active principle [20,52]. Clinical evidence and regulatory landscape Human evidence remains limited. Two registered studies are often cited in the field: one investigating grape-derived exosomes for oral mucositis in head and neck cancer (NCT01668849) and another evaluating plant exosomes for curcumin delivery to normal and colon cancer tissue (NCT01294072) [53,54]. Public peer-reviewed outcome data remain sparse, so claims of near-term clinical translation should be cautious. Regulatory positioning is also unsettled. Depending on composition, indication, and manufacturing route, a PDEV product might resemble a botanical product, a biologic, a drug-delivery platform, or a nanomedicine. Clear analytical standards will be needed before any category becomes workable. Realistic next steps Near-term progress will likely depend on practical work rather than broad claims of natural safety. Priorities include source-controlled comparative studies, storage-validated reference materials, route-specific pharmacokinetic testing, cargo-depletion or rescue experiments, and formulation studies that connect vesicle biology to a product concept. Infectious disease, oncology, and RNA delivery deserve continued exploration, but each should be pursued with explicit pharmacology. With these foundations, PDEVs could move from an interesting cross-kingdom phenomenon to a tractable class of pharmaceutical materials. Conclusion PDEVs are attractive because they combine accessible sourcing, oral or local route compatibility, and biologically active cargo in a single nanoscale platform. The strongest preclinical evidence currently lies in bone repair and gastrointestinal inflammation, while cancer, urinary disease, RNA delivery, and other applications remain earlier-stage but promising. The engineered use of PDEVs as drug delivery carriers adds pharmaceutical versatility beyond endogenous bioactivity. Progress now depends less on identifying additional plant sources and more on building the technical framework required for reproducible development. Standardization, mechanism-resolved potency testing, and clinically relevant pharmacology will determine whether PDEVs become credible therapeutic products. CRediT authorship contribution statement Jingcheng Yu: Data curation, Formal analysis, Writing – original draft, Writing – review & editing. Yuren Shen: Supervision, Writing – original draft. Hao Jia: Conceptualization, Funding acquisition, Writing – review & editing. Declaration of competing interest The authors declare no conflict of interest.